This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Fedratinib for Myelofibrosis

< Back

Fedratinib for Myelofibrosis


Cancer and Palliative Care

June 2018

Myelofibrosis is a cancer of the bone marrow in which the marrow is replaced by scar tissue. The early stages of myelofibrosis may be asymptomatic in some people while others may have severe symptoms from the onset. As the bone marrow becomes more scarred, it is less able to produce blood cells leading to enlargement of spleen and liver. Enlargement of spleen may cause abdominal pain, shortness of breath, early satiety and faecal incontinence, along with progressive anaemia. Other symptoms include incurable itch, general malaise, weight loss, night sweats, low grade fever, anaemia, fatigue, and pallor. Many people with myelofibrosis have mutations in a gene known as JAK2 gene.
Fedratinib is in development for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, including patients who have been previously exposed with ruxolitinib. Fedratinib is an inhibitor of JAK2 with potential to kill cancer cells. Fedratinib is given by mouth as capsule. If licensed fedratinib will offer an additional option for the treatment for patients with myelofibrosis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts